Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Non-Current Deffered Revenue (2022 - 2025)

Historic Non-Current Deffered Revenue for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $8.7 million.

  • Orchestra BioMed Holdings' Non-Current Deffered Revenue fell 2430.28% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 2430.28%. This contributed to the annual value of $11.0 million for FY2024, which is 2636.2% down from last year.
  • According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Non-Current Deffered Revenue is $8.7 million, which was down 2430.28% from $9.6 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' Non-Current Deffered Revenue's 5-year high stood at $14.9 million during Q4 2023, with a 5-year trough of $5.6 million in Q3 2022.
  • In the last 4 years, Orchestra BioMed Holdings' Non-Current Deffered Revenue had a median value of $12.7 million in 2024 and averaged $11.7 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first soared by 14723.21% in 2023, then crashed by 2636.2% in 2024.
  • Orchestra BioMed Holdings' Non-Current Deffered Revenue (Quarter) stood at $13.1 million in 2022, then increased by 13.89% to $14.9 million in 2023, then dropped by 26.36% to $11.0 million in 2024, then decreased by 21.2% to $8.7 million in 2025.
  • Its last three reported values are $8.7 million in Q3 2025, $9.6 million for Q2 2025, and $10.8 million during Q1 2025.